ZyVersa Therapeutics, Inc. (ZVSA)
PNK · Biotechnology
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial for the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100 a humanized monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of numerous inflammatory diseases, with cardiometabolic conditions associated with obesity as the lead. The company has a license agreement with L&F Research LLC, and InflamaCORE, LLC. ZyVersa Therapeutics, Inc. was founded in 2014 and is based in Weston, Florida.
Peers in Healthcare
ZyVersa Therapeutics, Inc. has no peer companies in this window.
Recent press releases
ZyVersa Therapeutics, Inc. has not issued a press release in this window.
SEC filings
All filings →ZyVersa Therapeutics, Inc. has not filed an SEC document in this window.
Insider trades
All insider trades →ZyVersa Therapeutics, Inc. has no reported insider trades in the last 90 days.